2026 Volume: 01 Issue: 08 ISSN 1671-2838 Page No: 98-108

Review Article

Pharmaceutical Care and Research

https://pcrjournal.com

Volume: 01
Issue: 08

EMERGING CONCEPTS IN CANCER TREATMENT: A HYPOTHESIS-BASED REVIEW

Murugan Karuppasamy*

Microbiologist, Department of Microbiology, JCC Marine Exports, Tuticorin District, Tamil Nadu, India.

Article Received: 01 October 2026
Article Revised: 20 October 2026
Published on: 10 November 2026

***Corresponding Author: Murugan Karuppasamy**
Microbiologist, Department of Microbiology, JCC Marine Exports, Tuticorin District, Tamil Nadu, India.

DOI: https://doi-doi.org/101555/ijpcr.6855

ABSTRACT

Cancer remains a major global health challenge because of its biological complexity, molecular heterogeneity, metastatic potential, and ability to develop resistance to treatment. Although conventional chemotherapy, radiotherapy, targeted therapy, and immunotherapy have improved clinical outcomes, therapeutic responses remain variable among patients. Recent advances in cancer biology have identified new opportunities for treatment through tumor-specific metabolic vulnerabilities, immune modulation, ferroptosis, micro environmental remodeling, and precision medicine. This review explores emerging concepts in cancer treatment and proposes a hypothesis-based framework for future therapeutic research. The central hypothesis is that cancer treatment efficacy may be improved by integrating tumor-specific metabolic targeting, immune reactivation, and tumor microenvironment remodeling through biomarker-guided therapeutic combinations. Recent literature published between 2021 and 2026 was examined using a narrative review approach. The findings suggest that cancer metabolism, immune-cell dysfunction, cellular heterogeneity, and acquired resistance are interconnected processes that may influence therapeutic outcomes. Emerging technologies, including single-cell multi-omics, spatial transcriptomics, liquid biopsy, and artificial intelligence, provide new opportunities to identify patient-specific therapeutic vulnerabilities. However, many proposed approaches remain experimental and require further validation in clinical studies. This review highlights the importance of hypothesis-driven research and interdisciplinary collaboration in developing safer, more effective, and personalized cancer treatments.

KEYWORDS: Cancer therapy; Therapeutic hypothesis; Immunotherapy; Cancer metabolism; Precision oncology; Personalized medicine

1. INTRODUCTION

Cancer is a group of diseases characterized by uncontrolled cellular proliferation, abnormal differentiation, genetic alterations, and the potential to invade surrounding tissues and metastasize to distant organs. Its biological complexity arises from interactions between cancer cells, immune cells, stromal components, blood vessels, and systemic metabolic factors.

Traditional cancer treatment approaches include surgery, chemotherapy, radiotherapy, hormone therapy, and molecularly targeted therapy. Immunotherapy, particularly immune checkpoint inhibition and adoptive cellular therapy, has introduced new opportunities for controlling malignant disease. Nevertheless, treatment outcomes remain inconsistent because tumors differ in molecular characteristics, immune composition, and sensitivity to therapeutic agents.

Cancer heterogeneity is a major challenge in clinical oncology. Different cell populations within a single tumor may exhibit distinct genetic, epigenetic, and metabolic characteristics. These differences can contribute to treatment failure and the emergence of resistant cell populations [1,2].

Recent research has also emphasized that cancer is not solely a disease of malignant cells. The tumor microenvironment (TME) influences tumor progression, immune evasion, and treatment sensitivity. Cancer-associated fibroblasts, immunosuppressive myeloid cells, extracellular matrix components, and altered vascular structures can collectively reduce therapeutic effectiveness [3,4].

These observations support the need for new therapeutic concepts that address the interconnected biological processes responsible for tumor survival and resistance.

2. AIM AND OBJECTIVES OF THE STUDY

Aim

To review emerging concepts in cancer treatment and develop a modern hypothesis for improving therapeutic efficacy through integrated, biomarker-guided approaches.

Objectives

1. To examine recent developments in cancer therapy, including immunotherapy, targeted therapy, and metabolic intervention.
2. To evaluate the role of tumor heterogeneity and the tumor microenvironment in treatment response and resistance.
3. To explore emerging therapeutic strategies involving ferroptosis, immunogenic cell death, and metabolic reprogramming.
4. To propose a hypothesis-based framework for future experimental and clinical cancer research.

3. MATERIALS AND METHODS

3.1 Review design

This article was developed as a hypothesis-based narrative review of emerging cancer treatment concepts. It integrates recent scientific literature with established biological principles to identify research opportunities and propose a testable therapeutic hypothesis.

3.2 Literature search strategy

Relevant literature was identified through searches of PubMed, Google Scholar, and scientific journal websites. Search terms included:

- Emerging cancer therapies
- Cancer immunotherapy
- Tumor microenvironment
- Cancer metabolism
- Ferroptosis and cancer
- Therapeutic resistance
- Precision oncology
- Single-cell multi-omics
- Hypothesis-driven cancer research

3.3 Selection criteria

The review prioritized peer-reviewed research articles, systematic reviews, and scientific perspectives published between January 2021 and October 2026.

Articles were considered relevant when they addressed cancer treatment mechanisms, emerging therapeutic approaches, biomarkers, treatment resistance, or future research directions.

Older foundational literature was not included in the reference list unless necessary to explain a specific historical concept.

3.4 Literature synthesis

The selected literature was organized into five major themes:

1. Cancer immunotherapy and immune reactivation
2. Metabolic vulnerabilities and metabolic intervention
3. Tumor microenvironment remodeling
4. Ferroptosis and immunogenic cell death
5. Precision medicine and therapeutic resistance

The findings were synthesized to develop a central hypothesis and identify future experimental approaches.

4. RESULTS AND DISCUSSION

4.1 Emerging concept 1: Cancer immunotherapy and immune reactivation

Cancer immunotherapy aims to enhance the ability of the immune system to recognize and eliminate malignant cells. Immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 have demonstrated clinical benefits in selected cancers.

However, not all patients respond to immunotherapy. Tumors may avoid immune recognition through antigen loss, impaired antigen presentation, immune-cell exclusion, and the development of immunosuppressive microenvironments.

Recent research suggests that immune dysfunction is influenced by interactions among cancer cells, immune cells, and metabolic pathways [5,6].

A modern therapeutic concept is to combine immune checkpoint inhibition with strategies that improve immune-cell infiltration or restore immune-cell function.

For example, therapeutic approaches that induce immunogenic cell death may increase the release of tumor-associated antigens and stimulate antitumor immune responses [7].

Hypothesis 1: Increasing tumor antigen availability while reducing immune suppression may improve the response to immune checkpoint inhibitors in selected cancers.

This hypothesis requires testing in tumor-specific experimental systems and clinical studies.

4.2 Emerging concept 2: Cancer metabolism as a therapeutic target

Cancer cells undergo metabolic reprogramming to support rapid proliferation, survival under stress, and adaptation to changing environmental conditions.

Metabolic changes may involve glucose utilization, amino acid metabolism, lipid synthesis, mitochondrial activity, and redox regulation. These processes are influenced by oxygen availability, nutrient supply, and interactions with the tumor microenvironment [8,9].

Cancer cells may also depend on metabolic pathways that are less essential to certain normal cells. These dependencies create potential therapeutic vulnerabilities.

However, metabolic targeting presents several challenges. Tumor cells may adapt by activating alternative pathways, while immune cells within the tumor also require metabolic resources to function effectively [10].

A proposed strategy is to identify metabolic dependencies in individual tumors and combine targeted metabolic intervention with immunotherapy.

Hypothesis 2: Biomarker-guided targeting of tumor-specific metabolic dependencies may increase treatment sensitivity while limiting disruption of normal tissues and antitumor immune cells.

4.3 Emerging concept 3: Remodeling the tumor microenvironment

The tumor microenvironment consists of cancer cells, immune cells, fibroblasts, endothelial cells, extracellular matrix, signaling molecules, and metabolic products.

This environment may support cancer progression and reduce the effectiveness of therapeutic agents. For example, cancer-associated fibroblasts may contribute to extracellular matrix remodeling, while immunosuppressive cells may inhibit cytotoxic T-cell activity.

The TME is increasingly recognized as an important therapeutic target rather than simply a passive structure surrounding the tumor [3,4,11].

Recent advances in single-cell sequencing and spatial transcriptomics allow researchers to investigate the spatial distribution and functional characteristics of cells within tumors.

These approaches may help identify specific micro environmental features associated with treatment resistance.

Hypothesis 3: Selective remodeling of immunosuppressive tumor microenvironments may improve the penetration, immune activity, and therapeutic effectiveness of existing anticancer treatments.

4.4 Emerging concept 4: Ferroptosis and alternative cell-death pathways

Ferroptosis is a regulated form of cell death associated with iron-dependent lipid peroxidation.

Unlike classical apoptosis, ferroptosis involves oxidative damage to cellular membranes and disruption of lipid homeostasis.

Research has identified ferroptosis as a potential therapeutic opportunity in cancers that exhibit particular metabolic or redox vulnerabilities [12,13].

However, the relationship between ferroptosis and cancer therapy is complex. Its effects may depend on tumor type, immune-cell interactions, and the biological context.

At present, ferroptosis-based cancer therapy remains an emerging research area, and its clinical application requires further investigation.

Hypothesis 4: Selective induction of ferroptosis in metabolically vulnerable cancer cells may complement established cancer treatments and reduce the survival of treatment-resistant tumor populations.

4.5 Emerging concept 5: Precision oncology and multi-omics integration

Precision oncology seeks to select treatments based on molecular characteristics of individual tumors.

Traditional approaches frequently rely on a limited number of biomarkers. However, cancer biology is complex, and multiple molecular pathways may influence therapeutic response.

Single-cell multi-omics can provide information about genetic alterations, gene expression, protein activity, and cellular states. Spatial transcriptomics adds information about the location of these features within tumor tissues [14,15].

Liquid biopsy approaches can also provide minimally invasive information about circulating tumor DNA and other cancer-associated biomarkers.

These technologies may support longitudinal monitoring of tumor evolution and treatment response [16].

Hypothesis 5: Integrating molecular, cellular, spatial, and circulating biomarkers may enable more accurate selection and adaptation of cancer treatment strategies.

4.6 Emerging concept 6: Preventing therapeutic resistance

Acquired resistance is a major cause of treatment failure.

Cancer cells may develop resistance through genetic alterations, epigenetic changes, altered signaling pathways, metabolic adaptation, and interactions with surrounding cells.

Resistance may also involve changes in cellular state rather than the acquisition of a new mutation.

Recent research emphasizes the importance of studying resistance as a dynamic process that develops during treatment [17,18].

This supports the concept of adaptive therapy, in which treatment strategies are modified according to tumor response and evolving biological characteristics.

Hypothesis 6: Dynamic biomarker monitoring combined with adaptive therapeutic strategies may delay or reduce the emergence of acquired resistance in selected cancers.

Table 1. Emerging concepts in cancer treatment.

Therapeutic concept	Biological target	Potential application
Immunotherapy	Immune checkpoints and immune-cell activity	Restoring antitumor immunity
Metabolic targeting	Tumor-specific metabolic dependencies	Reducing cancer-cell survival
TME remodeling	Stromal and immunosuppressive components	Improving treatment sensitivity
Ferroptosis	Iron-dependent lipid peroxidation	Eliminating vulnerable cancer cells
Precision oncology	Molecular and cellular biomarkers	Individualized treatment selection

Table 2. Proposed therapeutic combinations.

Combination strategy	Proposed mechanism	Major challenge
Immunotherapy + metabolic targeting	Improve immune activity and tumor control	Metabolic effects on immune cells
Immunotherapy + TME remodeling	Reduce immune suppression	Tumor-specific microenvironment
Targeted therapy + immunotherapy	Inhibit oncogenic pathways and activate immunity	Treatment toxicity
Ferroptosis induction + targeted therapy	Increase cancer-cell vulnerability	Selectivity and safety
Biomarker monitoring + adaptive therapy	Adjust treatment to tumor evolution	Clinical validation

Table 3. Biomarkers for hypothesis-driven cancer research.

Biomarker category	Examples	Potential research use
Genomic	Driver mutations	Target selection
Immune	PD-L1, immune-cell infiltration	Immunotherapy response
Metabolic	Metabolic enzyme expression	Metabolic vulnerability
Circulating	Circulating tumor DNA	Disease monitoring
Spatial	Cell distribution and interactions	TME characterization

Table 4. Modern therapeutic hypotheses.

Hypothesis	Proposed intervention	Expected outcome
H1	Increase tumor antigen availability	Improved immune recognition
H2	Target tumor-specific metabolic dependencies	Reduced tumor survival
H3	Remodel immunosuppressive TME	Improved treatment sensitivity
H4	Induce selective ferroptosis	Elimination of vulnerable cancer cells
H5	Integrate multi-omics biomarkers	More precise treatment selection

Table 5. Research gaps and future directions

Research gap	Proposed approach	Expected contribution
Tumor heterogeneity	Single-cell analysis	Identification of resistant cell populations
Treatment resistance	Longitudinal biomarker monitoring	Earlier detection of resistance
Metabolic adaptation	Functional metabolic studies	Identification of new therapeutic targets
TME complexity	Spatial transcriptomics	Mapping of tumor-immune interactions
Limited clinical translation	Biomarker-guided trials	Evaluation of therapeutic hypotheses




Figure 1. Integrated model of emerging cancer treatment.

Figure legend: Conceptual representation of the biological processes contributing to cancer treatment resistance and the proposed integrated therapeutic approach. This is an original conceptual model, not an experimentally validated pathway.




Figure 2. Hypothesis-driven therapeutic framework.

Figure legend: A proposed workflow for translating molecular discoveries into biomarker-guided cancer treatment strategies.




Figure 3. Proposed relationship between tumor metabolism and immune response.

Figure legend: Hypothetical relationship between tumor metabolic adaptation and immune dysfunction, with a proposed intervention designed to improve antitumor activity.

5. PROPOSED MODERN RESEARCH HYPOTHESIS

5.1 Central hypothesis

The therapeutic effectiveness of cancer treatment may be improved by combining biomarker-guided metabolic targeting, immune reactivation, and tumor microenvironment remodeling to selectively disrupt cancer-cell survival while preserving antitumor immune function.

5.2 Scientific rationale

This hypothesis is based on the observation that tumor metabolism, immune-cell activity, and micro environmental conditions are interconnected.

A cancer cell may survive treatment by changing its metabolic pathways, while the surrounding microenvironment may reduce immune recognition or limit drug penetration.

Therefore, targeting a single pathway may be insufficient in some cancers.

An integrated approach may provide a broader therapeutic effect by addressing several biological mechanisms simultaneously.

5.3 Proposed experimental validation

The hypothesis could be tested using:

1. Cancer cell lines with different metabolic characteristics.
2. Tumor organoids or other patient-derived tumor models.
3. Co-culture systems involving cancer and immune cells.
4. Molecular and metabolic biomarker analysis.
5. Appropriate controls and treatment-combination groups.
6. Functional evaluation of cell viability, immune activity, and treatment response.

A subsequent clinical study could evaluate the safety and efficacy of selected combinations in biomarker-defined patient populations.

6. LIMITATIONS AND FUTURE PERSPECTIVES

The proposed therapeutic framework has several limitations.

First, cancer is highly heterogeneous, and a treatment strategy effective in one tumor type may not be effective in another.

Second, metabolic pathways are shared by cancer cells and normal cells. Therapeutic interventions may therefore produce unwanted effects.

Third, the tumor microenvironment varies across cancer types and between patients.

Fourth, many emerging therapeutic concepts remain at the preclinical stage.

Future research should prioritize rigorous experimental validation, patient-specific biomarker development, and carefully designed clinical trials.

The integration of artificial intelligence, multi-omics technologies, and longitudinal clinical data may improve the identification of therapeutic vulnerabilities.

Nevertheless, computational predictions and experimental observations should not be interpreted as evidence of clinical efficacy without appropriate validation.

7. CONCLUSION

Emerging concepts in cancer treatment demonstrate the importance of understanding cancer as a complex biological system involving malignant cells, immune responses, metabolic pathways, and the tumor microenvironment. Although current therapies have improved outcomes for many patients, therapeutic resistance and variable treatment responses remain significant challenges.

This review proposes that integrating tumor-specific metabolic targeting, immune reactivation, and micro environmental remodelling may provide a promising direction for future cancer research. The central hypothesis emphasizes the need to identify biological vulnerabilities through molecular and cellular biomarkers and to develop therapeutic combinations based on the characteristics of individual tumors.

Emerging approaches such as ferroptosis induction, immunogenic cell death, single-cell multi-omics, spatial transcriptomics, and liquid biopsy may support the development of more precise therapeutic strategies. However, their effectiveness, safety, and clinical applicability require further investigation.

In conclusion, hypothesis-driven cancer research should focus on identifying the biological mechanisms responsible for treatment resistance and developing interventions that selectively target those mechanisms. Interdisciplinary collaboration among microbiologists, molecular biologists, immunologists, oncologists, and computational researchers will be essential for translating emerging concepts into clinically meaningful cancer treatments.

Acknowledgements

The author would like to express his sincere gratitude to all individuals and institutions that provided support, encouragement, and valuable suggestions during the preparation of this review article. The author also acknowledge the contributions of researchers and scientific communities whose published work has significantly advanced our understanding of emerging cancer therapies and hypothesis-based therapeutic approaches.

REFERENCES

1. Demicco M, Liu XZ, Leithner K, Fendt SM. Metabolic heterogeneity in cancer. *Nat Metab.* 2024;6(1):18-38. doi: 10.1038/s42255-023-00963-z.
2. Soragni A, Knudsen ES, O'Connor TN, Tognon CE, Tyner JW, Gini B, et al. Acquired resistance in cancer: towards targeted therapeutic strategies. *Nat Rev Cancer.* 2025;25(8):613-633. doi: 10.1038/s41568-025-00824-9.
3. Sinha A, Ghosh D, Karati D. Tumor microenvironment and immunotherapy: from bench to bedside. *Med Oncol.* 2025;42(7):244. doi: 10.1007/s12032-025-02818-x.

4. Xu S, Li X, Ma W. Redefining the tumor microenvironment with emerging therapeutic strategies. *Oncol Res.* 2024;32(11):1701-1708. doi: 10.32604/or.2024.055161.
5. Dang Q, Li B, Jin B, Ye Z, Lou X, Wang T, et al. Cancer immunometabolism: advent, challenges, and perspective. *Mol Cancer.* 2024;23(1):72. doi: 10.1186/s12943-024-01981-5.
6. Hanahan D, Michielin O, Pittet MJ. Convergent inducers and effectors of T cell paralysis in the tumour microenvironment. *Nat Rev Cancer.* 2025;25(1):41-58. doi: 10.1038/s41568-024-00761-z.
7. Galluzzi L, Guilbaud E, Schmidt D, Kroemer G, Marincola FM. Targeting immunogenic cell stress and death for cancer therapy. *Nat Rev Drug Discov.* 2024;23(6):445-460. doi: 10.1038/s41573-024-00920-9.
8. Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. *Nat Rev Drug Discov.* 2021;21(2):141-162. doi: 10.1038/s41573-021-00339-6.
9. Altea-Manzano P, Decker-Farrell A, Janowitz T, Erez A. Metabolic interplays between the tumour and the host shape the tumour macroenvironment. *Nat Rev Cancer.* 2025;25(4):274-292. doi: 10.1038/s41568-024-00786-4.
10. Trefny MP, Kroemer G, Zitvogel L, Kobold S. Metabolites as agents and targets for cancer immunotherapy. *Nat Rev Drug Discov.* 2025;24(10):764-784. doi: 10.1038/s41573-025-01227-z.
11. Zabransky DJ, Yarchoan M, Jaffee EM. Strategies for heating up cold tumors to boost immunotherapies. *Annu Rev Cancer Biol.* 2023;7:149-170. doi: 10.1146/annurev-cancerbio-061421-040258.
12. Ubellacker JM, Dixon SJ. Prospects for ferroptosis therapies in cancer. *Nat Cancer.* 2025;6(8):1326-1336. doi: 10.1038/s43018-025-01037-7.
13. Berndt C, Alborzinia H, Amen VS, Ayton S, Barayeu U, Bartelt A, et al. Ferroptosis in health and disease. *Redox Biol.* 2024;75:103211. doi: 10.1016/j.redox.2024.103211.
14. Le J, Dian Y, Zhao D, Guo Z, Luo Z, Chen X, et al. Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment. *Mol Cancer.* 2025;24(1):221. doi: 10.1186/s12943-025-02426-3.
15. Zhu J, Zhang K, Chen Y, Ge X, Wu J, Xu P, et al. Progress of single-cell RNA sequencing combined with spatial transcriptomics in tumour microenvironment and treatment of pancreatic cancer. *J Transl Med.* 2024;22(1):563. doi: 10.1186/s12967-024-05307-3.
16. Passaro A, Al Bakir M, Hamilton EG, Diehn M, André F, Roy-Chowdhuri S, et al. Cancer biomarkers: emerging trends and clinical implications for personalized treatment. *Cell.* 2024;187(7):1617-1635. doi: 10.1016/j.cell.2024.02.041.
17. McHugh D, Durán I, Gil J. Senescence as a therapeutic target in cancer and age-related diseases. *Nat Rev Drug Discov.* 2025;24(1):57-71. doi: 10.1038/s41573-024-01074-4.
18. Ohshima K. The landscape of cancer metabolism as a therapeutic target. *Pathol Int.* 2025;75(8):387-402. doi: 10.1111/pin.70034.